<DOC>
	<DOC>NCT01161511</DOC>
	<brief_summary>This is an open-label, multi-dose, single-arm, Phase 1, dose-escalation study of XmAb5574. The study was conducted to identify the maximum tolerated dose (MTD) and/or recommended dose(s) (RD) for further study, to characterize safety and tolerability, to characterize PK, PD and immunogenicity, and to evaluate preliminary antitumor activity of XmAb5574 in patients with relapsed or refractory CLL/SLL.</brief_summary>
	<brief_title>Safety and Tolerability of XmAbÂ®5574 in Chronic Lymphocytic Leukemia</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia, Lymphoid</mesh_term>
	<mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
	<criteria>relapsed or refractory CLL/SLL at least 18 years of age able to receive outpatient treatment and followup at the treating institution completed all CLL therapies &gt; 4 weeks prior to first study dose previously treated with an antiCD19 antibody therapy undergone prior allogeneic stem cell transplantation within 6 months or having active graft versus host disease active Richter's syndrome designated Class III or IV by the New York Heart Association (NYHA) criteria history of myocardial infarction or stroke within the last 6 months active viral, bacterial, or systemic fungal infection requiring treatment HIV or Hepatitis C positive Hepatitis B infection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>CLL</keyword>
	<keyword>SLL</keyword>
	<keyword>CD19</keyword>
</DOC>